Cargando…
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. I...
Autores principales: | Váradi, Melinda, Horváth, Orsolya, Módos, Orsolya, Fazekas, Tamás, Grunewald, Camilla M., Niegisch, Günter, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Olah, Csilla, Maráz, Anikó, Furka, Andrea, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575904/ https://www.ncbi.nlm.nih.gov/pubmed/37833455 http://dx.doi.org/10.1038/s41598-023-44103-9 |
Ejemplares similares
-
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021) -
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022) -
Why are upper tract urothelial carcinoma two different diseases?
por: Szarvas, Tibor, et al.
Publicado: (2016) -
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022) -
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)